Central retinal vein occlusion

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:411527H34.8
Who is this for?
Show terms as
2FDA treatments27Active trials129Specialists8Treatment centers1Financial resources

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Central retinal vein occlusion (CRVO) is a condition where the main vein that drains blood from the retina (the light-sensitive tissue at the back of the eye) becomes blocked. When this vein is blocked, blood and fluid back up into the retina, causing swelling, bleeding, and damage to the delicate tissue needed for vision. This leads to sudden, painless vision loss in the affected eye, which can range from mild blurriness to severe loss of sight. CRVO is sometimes called a "retinal stroke" because, like a stroke in the brain, it involves a blockage of blood flow. The condition is more common in older adults and in people who have high blood pressure, diabetes, glaucoma, or blood clotting disorders. It can affect one or both eyes, though one eye is more typical. Treatment focuses on managing complications and preserving as much vision as possible. Anti-VEGF injections (medications injected into the eye) are the main treatment and help reduce swelling in the retina. Steroid implants may also be used. Laser treatment was once the standard but is now used less often. Managing underlying conditions like high blood pressure and diabetes is also a critical part of care. While some people recover good vision, others may experience lasting vision problems, and complications like abnormal blood vessel growth (neovascularization) can lead to further issues if not treated promptly.

Also known as:

Key symptoms:

Sudden painless vision loss in one eyeBlurry or distorted visionDark spots or floaters in visionLoss of central visionDifficulty reading or recognizing facesColors appearing washed out or different between eyesA dark or missing area in your field of visionGradual worsening of vision over days to weeksEye pain or pressure (in severe cases with complications)Redness of the eye (in advanced cases)

Clinical phenotype terms (16)— hover any for plain English
Cystoid macular edemaHP:0011505Macular cotton wool spotHP:0030497Intraretinal hemorrhageHP:0031805PapilledemaHP:0001085Retinal vascular tortuosityHP:0012841Macular edemaHP:0040049Macular degenerationHP:0000608Large central visual field defectHP:0001129Abnormal anterior eye segment morphologyHP:0004328ERG: Reduced dark-adapted b-wave amplitudeHP:0007984Retinal neovascularizationHP:0030666Epiretinal membraneHP:0100014
Inheritance

Multifactorial

Caused by a mix of several genes and environmental factors

Age of Onset

Adult

Begins in adulthood (age 18 or older)

Orphanet ↗NORD ↗

FDA & Trial Timeline

10 events
Jun 2026Speculum-Free Intravitreal Injection Using Cotton-Tipped Applicator Retraction: A Randomized Trial of Pain, Procedure Time, Patient Satisfaction, and Safety

Jakkrit Juhong — NA

TrialNOT YET RECRUITING
May 2026Study of the SCD411 Prefilled Syringe for Treating Adults With Wet Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, or Diabetic Retinopathy

Sam Chun Dang Pharm. Co. Ltd. — PHASE2

TrialNOT YET RECRUITING
Apr 2026Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal Injections

Harrow Inc — PHASE4

TrialNOT YET RECRUITING
Feb 2026AI-Assisted Detection of Posterior Segment Diseases: DR, AMD, RVO, and Glaucoma

Inje University — NA

TrialENROLLING BY INVITATION
Jan 2026DATA-INSIGHT is a Project That Looks at Health Data in Germany to Find Out How Many Patients Suffer From Eye Disease. The Project Also Explores New Ways to Collect and Use Publicly Available Healthcare Information.

Bayer

TrialNOT YET RECRUITING
Jan 2026An Assistant Model for Anti-VEGF Therapy Decision

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine — NA

TrialNOT YET RECRUITING
Nov 2025Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Diabetic Retinopathy or Retinal Vein Occlusion

Annexin Pharmaceuticals AB — PHASE2

TrialRECRUITING
Nov 2025Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium

MediBeacon — EARLY_PHASE1

TrialRECRUITING
Nov 2025A Phase 2a Study to Evaluate the Safety, Tolerability, and Efficacy of SNP318 in DME Patients

SciNeuro — PHASE2

TrialNOT YET RECRUITING
Oct 2025Effectiveness of Intravitreal Injection of Aflibercept 8 mg in Resistant Diabetic Macular Edema, Retinal Vein Occlusion and Myopic Choroidal Neovascularisation Patients

Tanta University — EARLY_PHASE1

TrialNOT YET RECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

2 available

Eylea

aflibercept· Regeneron Pharmaceuticals, Inc.

indicated for the treatment of patients with Macular Edema Following Retinal Vein Occlusion (RVO)

Ozurdex

dexamethasone intravitreal implant· Allergan

The treatment of macular edema following branch retinal vein occlusion (BRVO)

Clinical Trials

20 recruitingView all trials with filters →
Phase 35 trials
A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 2)
Phase 3
Active
PI: Diana Do, MD (Stanford Byers Eye Institute) · Sites: Gilbert, Arizona; Phoenix, Arizona +60 more · Age: 1885 yrs
A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME
Phase 3
Actively Recruiting
PI: Clinical Trials (Hoffmann-La Roche) · Sites: Mesa, Arizona; Phoenix, Arizona +90 more · Age: 1899 yrs
Combination of Ranibizumab and Targeted Laser Photocoagulation
Phase 3
Actively Recruiting
PI: Matus Rehak, Professor (Department of Ophthalmology Justus-Liebig-Universi) · Sites: Innsbruck; Dresden +13 more · Age: 1899 yrs
A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders
Phase 3
Active
· Sites: Springfield, Illinois; Hagerstown, Maryland +1 more · Age: 1899 yrs
A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema
Phase 3
Actively Recruiting
PI: Dr. Niaz Abdur Rahman (Managing Director, Bangladesh Eye Hospital & Insti) · Sites: Dhaka · Age: 1899 yrs
Phase 41 trial
Brolucizumab Efficacy and Safety Single-Arm Descriptive Trial in Patients With Persistent Diabetic Macular Edema
Phase 4
Active
PI: Honghua Yu (Guangdong Provincial People's Hospital) · Sites: Guangzhou, Guangdong · Age: 1899 yrs
Phase 23 trials
A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO
Phase 2
Actively Recruiting
PI: Charles Miller, MD PhD (EyeBiotech Ltd.) · Sites: Scottsdale, Arizona; Scottsdale, Arizona +47 more · Age: 1899 yrs
Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Diabetic Retinopathy or Retinal Vein Occlusion
Phase 2
Actively Recruiting
PI: Anna Frostegård, MD, PhD (Annexin Pharmaceuticals AB) · Sites: London · Age: 1899 yrs
Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME)
Phase 2
Actively Recruiting
· Sites: Reno, Nevada · Age: 2589 yrs
Phase 12 trials
MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema
Phase 1
Actively Recruiting
PI: Kai Zhang, MD (Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.) · Sites: Changsha, Hunan; Chengdu, Sichuan +1 more · Age: 1899 yrs
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7497372 in Participants With Diabetic Macular Edema (DME)
Phase 1
Active
PI: Clinical Trials (Hoffmann-La Roche) · Sites: Mesa, Arizona; Peoria, Arizona +36 more · Age: 1899 yrs
N/A1 trial
Home- vs Hospital-based Care of Anti-VEGF Treatment for Diabetic Macular Edema: Non-inferiority RCT
N/A
Actively Recruiting
PI: Yizhi Liu, MD, PhD (Zhongshan Ophthalmic Center, Sun Yat-sen Universit) · Sites: Dongguan, Guangdong; Foshan, Guangdong +1 more · Age: 1899 yrs
Other7 trials
Epidemiologic Assessment of Diabetic Retinopathy in Egypt Using Ultrawide Field Fundus Photographs
Actively Recruiting
· Sites: Alexandria · Age: 1899 yrs
Aqueous Humor Proteome in Retinal Vein Occlusion With Macular Edema
Active
· Sites: Tianjin, Province · Age: 2080 yrs
Implementation of the Intravitreal Injection Administered by Nurses
Enrolling by Invitation
· Sites: Sabadell, Barcelona · Age: 1899 yrs
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
Active
PI: Clinical Trials (Hoffmann-La Roche) · Sites: Phoenix, Arizona; Pasadena, California +297 more · Age: 1899 yrs
Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)
Actively Recruiting
PI: Clinical Trials (Hoffmann-La Roche) · Sites: Shantou, Guangdong; Luoyang, Henan +39 more · Age: 1899 yrs
Observational Study of Adult Participants With Diabetic Macular Edema and Suboptimal Response to Anti-Vascular Endothelial Growth Factor Treated With Dexamethasone Intravitreal Implant
Active
PI: ABBVIE INC. (AbbVie) · Sites: Edegem, Antwerpen; Brussels, Brussels Capital +52 more · Age: 1899 yrs
Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT)
Active
PI: Adam Turpcu, Ph.D. (Adverum Biotechnologies) · Sites: Beverly Hills, California; Reno, Nevada +5 more · Age: 1899 yrs

Specialists

Showing 25 of 129View all specialists →
AM
Agnès GLACET-BERNARD, MD
Specialist
PI on 1 active trial1 Central retinal vein occlusion publication
MM
Michael Koss, MD
LOS ANGELES, CA
Specialist
PI on 2 active trials
RM
Roman Rubio, M.D.
REDWOOD CITY, CA
Specialist
PI on 2 active trials
HM
Harvey S Uy, MD
Specialist
PI on 2 active trials
AF
Anna Frostegård
Specialist
PI on 1 active trial
MM
Martine MAUGET FAYSSE, MD
Specialist
PI on 2 active trials
RM
Richard F. Spaide, M.D.
NEW YORK, NY
Specialist
PI on 2 active trials
HP
Hyoung Jun Koh, MD, PhD
Specialist
PI on 1 active trial
TO
Tetsuro Oshika
Specialist
2 Central retinal vein occlusion publications
RS
Rita Serra
Specialist
1 Central retinal vein occlusion publication
SM
Shohei Morikawa
Specialist
2 Central retinal vein occlusion publications
AZ
Angelo Zinellu
Specialist
1 Central retinal vein occlusion publication
FO
Fumiki Okamoto
Specialist
2 Central retinal vein occlusion publications
MS
Masahiko Shimura
Specialist
3 Central retinal vein occlusion publications
BH
Bent Honoré
Specialist
2 Central retinal vein occlusion publications
YS
Yoshimi Sugiura
Specialist
2 Central retinal vein occlusion publications
AP
Antonio Pinna
WESTON, FL
Specialist
1 Central retinal vein occlusion publication
HV
Henrik Vorum
Specialist
3 Central retinal vein occlusion publications
RK
Rahul N Khurana
SEATTLE, WA
Specialist
2 Central retinal vein occlusion publications
KK
Kentaro Kojima
Specialist
2 Central retinal vein occlusion publications
TM
Tomoya Murakami
Specialist
2 Central retinal vein occlusion publications
LC
Lasse Jørgensen Cehofski
Specialist
2 Central retinal vein occlusion publications
TH
Takahiro Hiraoka
Specialist
2 Central retinal vein occlusion publications
PM
Pablo Velazquez-Martin, MD
Specialist
PI on 8 active trials
TM
Thomas Ciulla, MD
CARMEL, IN
Specialist
PI on 8 active trials

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Financial Resources

1 resources
Eylea(aflibercept)Regeneron Pharmaceuticals, Inc.

Travel Grants

No travel grants are currently matched to Central retinal vein occlusion.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Central retinal vein occlusionForum →

No community posts yet. Be the first to share your experience with Central retinal vein occlusion.

Start the conversation →

Latest news about Central retinal vein occlusion

Disease timeline:

New recruiting trial: Mecobalamin Combined With Anti-VEGF Intravitreal Injection for Retinal Vein Occlusion Treatment

A new clinical trial is recruiting patients for Central retinal vein occlusion

New recruiting trial: Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)

A new clinical trial is recruiting patients for Central retinal vein occlusion

New recruiting trial: Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease

A new clinical trial is recruiting patients for Central retinal vein occlusion

New recruiting trial: Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium

A new clinical trial is recruiting patients for Central retinal vein occlusion

New recruiting trial: Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Diabetic Retinopathy or Retinal Vein Occlusion

A new clinical trial is recruiting patients for Central retinal vein occlusion

New recruiting trial: Effect of Video Viewing on Intravitreal Injection Experience

A new clinical trial is recruiting patients for Central retinal vein occlusion

New recruiting trial: A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO

A new clinical trial is recruiting patients for Central retinal vein occlusion

New recruiting trial: Combination of Ranibizumab and Targeted Laser Photocoagulation

A new clinical trial is recruiting patients for Central retinal vein occlusion

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.Is my CRVO the non-ischemic or ischemic type, and what does that mean for my vision?,How often will I need eye injections, and how long will treatment continue?,What underlying health conditions should I be tested for or manage more aggressively?,What are the warning signs that my condition is getting worse or developing complications?,Should I be tested for blood clotting disorders, especially if I am younger?,What can I do to protect the vision in my other eye?,Are there low-vision resources or rehabilitation services that could help me?

Common questions about Central retinal vein occlusion

What is Central retinal vein occlusion?

Central retinal vein occlusion (CRVO) is a condition where the main vein that drains blood from the retina (the light-sensitive tissue at the back of the eye) becomes blocked. When this vein is blocked, blood and fluid back up into the retina, causing swelling, bleeding, and damage to the delicate tissue needed for vision. This leads to sudden, painless vision loss in the affected eye, which can range from mild blurriness to severe loss of sight. CRVO is sometimes called a "retinal stroke" because, like a stroke in the brain, it involves a blockage of blood flow. The condition is more common

How is Central retinal vein occlusion inherited?

Central retinal vein occlusion follows a multifactorial inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Central retinal vein occlusion typically begin?

Typical onset of Central retinal vein occlusion is adult. Age of onset can vary across affected individuals.

Are there clinical trials for Central retinal vein occlusion?

Yes — 20 recruiting clinical trials are currently listed for Central retinal vein occlusion on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Central retinal vein occlusion?

25 specialists and care centers treating Central retinal vein occlusion are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.

What treatment and support options exist for Central retinal vein occlusion?

2 patient support programs are currently tracked on UniteRare for Central retinal vein occlusion. See the treatments and support programs sections for copay assistance, eligibility, and contact details.